Citius Pharmaceuticals, Inc. (CTXR)
Nasdaq · Healthcare · Biotechnology
$0.52−2.18%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $14.3M
- 52-week range
- $0.469 – $2.19
- 52-week change
- −62.00%
- EPS (trailing)
- −$1.75
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Headquarters: Cranford, United States · 23 employees · citiuspharma.com